SUN PHARMACEUTICAL INDUSTRIES: Q3 EBITDA 49.4B RUPEES VS 40.08B (YOY) || Q3 EBITDA MARGIN 32% VS 29.30% (YOY)

SUN PHARMACEUTICAL INDUSTRIES: Q3 REVENUE 155.2B RUPEES VS 136.7B (YOY)

SUN PHARMACEUTICAL INDUSTRIES: Q3 CONS NET PROFIT 33.6B RUPEES VS 29B (YOY)

MEGHMANI ORGANICS: Q3 EBITDA 377M RUPEES VS 408M (YOY) || Q3 EBITDA MARGIN 7.42% VS 7.18% (YOY)

MEGHMANI ORGANICS: Q3 REVENUE 5.08B RUPEES VS 5.7B (YOY)

MEGHMANI ORGANICS: Q3 CONS NET LOSS -43.5M RUPEES VS -44M (YOY)

PUDUMJEE PAPER PRODUCTS: Q3 EBITDA 328M RUPEES VS 310M (YOY) || Q3 EBITDA MARGIN 16.12% VS 15.99% (YOY)

PUDUMJEE PAPER PRODUCTS: Q3 REVENUE 2.03B RUPEES VS 1.9B (YOY)

PUDUMJEE PAPER PRODUCTS: Q3 SL NET PROFIT 207M RUPEES VS 196M (YOY)

CLEAN SCIENCE AND TECHNOLOGY: Q3 EBITDA 722M RUPEES VS 984M (YOY) || Q3 EBITDA MARGIN 33% VS 40.80% (YOY)

CLEAN SCIENCE AND TECHNOLOGY: Q3 REVENUE 2.1B RUPEES VS 2.4B (YOY)

CLEAN SCIENCE AND TECHNOLOGY: Q3 CONS NET PROFIT 459M RUPEES VS 656M (YOY)

SHILCHAR TECHNOLOGIES: Q3 REVENUE 1.70B RUPEES VS 1.5B (YOY)

SHILCHAR TECHNOLOGIES: Q3 EBITDA 525M RUPEES VS 431M (YOY) || Q3 EBITDA MARGIN 31% VS 28% (YOY)

SHILCHAR TECHNOLOGIES: Q3 SL NET PROFIT 423M RUPEES VS 345M (YOY)

ARFIN INDIA: Q3 EBITDA 112.2M RUPEES VS 94.7M (YOY) || Q3 EBITDA MARGIN 5.97% VS 5.25% (YOY)

ARFIN INDIA: Q3 REVENUE 1.87B RUPEES VS 1.80B (YOY)